Conversely, CYP1A2 has been observed to be suppressed in obese and NAFLD patients, and finally those drugs which are dependent on CYP1A2 oxidation such as theophylline are eliminated slowly in these individuals [12]. This evidence concerns the gene CYP1A2 and metabolic dysfunction-associated steatotic liver disease.